The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013).
 
Yasuhide Yamada
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Junki Mizusawa
No Relationships to Disclose
 
Satoru Iwasa
Honoraria - Lilly Japan; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst)
 
Shigenori Kadowaki
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly Japan (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Norisuke Nakayama
No Relationships to Disclose
 
Mizutomo Azuma
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly Japan (Inst); Taiho Pharmaceutical (Inst)
 
Takeshi Sakamoto
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Tatsuya Okuno
No Relationships to Disclose
 
Keisho Chin
No Relationships to Disclose
 
Akira Nozaki
Research Funding - Daiichi Sankyo (Inst)
 
Masaki Nakamura
No Relationships to Disclose
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroshi Katayama
Honoraria - Johnson & Johnson
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Takaki Yoshikawa
Honoraria - Abbott Nutrition; Ajinomoto; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson; Lilly; Medtronic; Nihonkayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; MSD Oncology; Novartis
Research Funding - Chugai Pharma; Novartis; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Takeshi Sano
Speakers' Bureau - Chugai Pharma; Johnson & Johnson; Lilly Japan; Medtronic; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Mitsuru Sasako
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo
 
Masanori Terashima
Honoraria - Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst)